Core Viewpoint - The company, Honghua Medical (00013), is set to experience several key events in 2026, including annual performance releases and significant new drug development progress [1]. Financial Performance - The company plans to hold a board meeting on March 5, 2026, to review and approve the annual performance for the year ending December 31, 2025 [2]. Business Development - The Phase III study of the novel spleen tyrosine kinase inhibitor, Solipinib, for the treatment of warm antibody autoimmune hemolytic anemia has met its primary endpoint. The company plans to submit a new drug application to the National Medical Products Administration of China in the first half of 2026 [3]. Product Development Progress - The company's antibody-drug conjugate platform candidates, HMPL-A580 and HMPL-A830, are expected to initiate Phase I clinical trials in 2026. Additionally, recent pipeline advancements include the acceptance and priority review of new drug applications for Vanregatinib and Savolitinib [4].
和黄医药2026年业绩发布与新药研发进展引关注